Patents by Inventor George Fromm

George Fromm has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterodimeric proteins and uses thereof
    Patent number: 11780897
    Abstract: The present invention relates, inter alia, to compositions and methods, including heterodimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity.
    Type: Grant
    Filed: March 24, 2021
    Date of Patent: October 10, 2023
    Assignee: Shattuck Labs, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
  • HETERODIMERIC PROTEINS AND USES THEREOF
    Publication number: 20230220030
    Abstract: The present invention relates, inter alia, to compositions and methods, including heterodimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity.
    Type: Application
    Filed: January 17, 2023
    Publication date: July 13, 2023
    Inventors: Taylor SCHREIBER, George FROMM, Suresh DE SILVA
  • Compositions and methods for adjoining type I and type II extracellular domains as heterologous chimeric proteins
    Patent number: 11654180
    Abstract: The present invention relates to, inter alia, compositions and methods, including chimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity. In part, the invention provides, in various embodiments, fusions of extracellular domains of transmembrane proteins that can have stimulatory or inhibitory effects.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: May 23, 2023
    Assignee: Heat Biologies, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva, Neal Schilling
  • Heterodimeric proteins for modulating gamma delta T cells
    Patent number: 11643447
    Abstract: The present technology relates, inter alia, to compositions and methods, including heterodimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity.
    Type: Grant
    Filed: June 1, 2022
    Date of Patent: May 9, 2023
    Assignee: Shattuck Labs, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
  • NK CELL-DIRECTED CHIMERIC PROTEINS
    Publication number: 20230045794
    Abstract: The present invention relates, inter alia, to compositions and methods, including chimeric proteins comprising an extracellular domain of a Type I transmembrane protein or a portion of a membrane-anchored extracellular protein and a portion of the extracellular domain of a Type II transmembrane protein, wherein the Type II transmembrane protein is naturally expressed on the surface of a Natural Killer (NK) cell that find use in the treatment of disease, such as cancer and viral infections.
    Type: Application
    Filed: April 14, 2022
    Publication date: February 16, 2023
    Inventors: Taylor SCHREIBER, Casey SHUPTRINE, George FROMM, Suresh DE SILVA
  • TGFBR2-BASED CHIMERIC PROTEINS
    Publication number: 20230048633
    Abstract: The present invention relates, in part, to, chimeric proteins which include the extracellular domain of transforming growth factor beta receptor (TGFBR2) and their use in the treatment of diseases, such as immunotherapies for cancer and/or an inflammatory disease.
    Type: Application
    Filed: May 20, 2022
    Publication date: February 16, 2023
    Inventors: Taylor SCHREIBER, Casey SHUPTRINE, George FROMM, Suresh DE SILVA
  • HETERODIMERIC PROTEINS FOR MODULATING GAMMA DELTA T CELLS
    Publication number: 20230020258
    Abstract: The present technology relates, inter alia, to compositions and methods, including heterodimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity.
    Type: Application
    Filed: June 1, 2022
    Publication date: January 19, 2023
    Inventors: Taylor SCHREIBER, George FROMM, Suresh DE SILVA
  • Compositions and methods for adjoining type I and type II extracellular domains as heterologous chimeric proteins
    Patent number: 11547742
    Abstract: The present invention relates to, inter alia, compositions and methods, including chimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity. In part, the invention provides, in various embodiments, fusions of extracellular domains of transmembrane proteins that can have stimulatory or inhibitory effects.
    Type: Grant
    Filed: September 20, 2021
    Date of Patent: January 10, 2023
    Assignee: Heat Biologics, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
  • METHODS OF MAKING AND USING EXTRACELLULAR DOMAIN-BASED CHIMERIC PROTEINS
    Publication number: 20220315637
    Abstract: The present invention relates, inter alia, to compositions and methods, including chimeric proteins and combination therapies that find use in the treatment of disease, such as cancer and/or an inflammatory disease.
    Type: Application
    Filed: April 11, 2022
    Publication date: October 6, 2022
    Inventors: Taylor SCHREIBER, George FROMM, Suresh DE SlLVA
  • CHIMERIC PROTEINS IN AUTOIMMUNITY
    Publication number: 20220306715
    Abstract: The present invention relates, inter alia, to compositions and methods, including chimeric proteins having a first domain comprising an extracellular domain of a first transmembrane protein, a first secreted protein, or a first membrane-anchored extracellular protein and a second domain comprising an extracellular domain of a second transmembrane protein, a second secreted protein, or a second membrane-anchored extracellular protein, in which either or both of the first domain and the second domain decreases self-directed immune system activity when bound to its ligand/receptor. Accordingly, the present invention find use in the treatment of autoimmune diseases.
    Type: Application
    Filed: August 28, 2020
    Publication date: September 29, 2022
    Inventors: Taylor SCHREIBER, George FROMM, Suresh DE SILVA, Louis GONZALEZ
  • CHIMERIC PROTEIN EXPRESSING T-CELLS
    Publication number: 20220259281
    Abstract: The present invention relates to, inter alia, compositions and methods, including engineered T cells that express chimeric antigen receptors and heterologous chimeric proteins that find use in the treatment of cancer.
    Type: Application
    Filed: June 22, 2020
    Publication date: August 18, 2022
    Inventors: Taylor SCHREIBER, George FROMM, Suresh DE SILVA
  • TIGIT- AND LIGHT-BASED CHIMERIC PROTEINS
    Publication number: 20220227831
    Abstract: The present invention relates, inter alia, to compositions and methods, including TIGIT- and/or LIGHT-based chimeric proteins that find use in the treatment of disease, such as cancer and an inflammatory disease.
    Type: Application
    Filed: April 6, 2022
    Publication date: July 21, 2022
    Inventors: Taylor SCHREIBER, George FROMM, Suresh DE SILVA
  • COMBINATION THERAPIES
    Publication number: 20220185863
    Abstract: The present invention relates to, inter alia, combinations of compositions which include chimeric proteins that find use in methods for treating disease, such as immunotherapies for cancer and autoimmunity.
    Type: Application
    Filed: February 27, 2020
    Publication date: June 16, 2022
    Inventors: Taylor SCHREIBER, George FROMM, Suresh DE SILVA
  • Methods of making and using extracellular domain-based chimeric proteins
    Patent number: 11332509
    Abstract: The present invention relates, inter alia, to compositions and methods, including chimeric proteins and combination therapies that find use in the treatment of disease, such as cancer and/or an inflammatory disease.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: May 17, 2022
    Assignee: Shattuck Labs, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
  • CSF1R-BASED CHIMERIC PROTEINS
    Publication number: 20220144909
    Abstract: The present invention relates, in part, to, chimeric proteins which include the extracellular domain of colony stimulating factor 1 receptor (CSF1R) and their use in the treatment of diseases, such as immunotherapies for cancer and/or an inflammatory disease.
    Type: Application
    Filed: January 28, 2022
    Publication date: May 12, 2022
    Inventors: Taylor SCHREIBER, George FROMM, Suresh DE SILVA
  • VSIG8-BASED CHIMERIC PROTEINS
    Publication number: 20220119481
    Abstract: The present invention relates, in part, to, chimeric proteins which include the extracellular domain of V-set and immunoglobulin domain-containing protein 8 (VSIG8) and their use in the treatment of diseases, such as immunotherapies for cancer and/or inflammatory diseases.
    Type: Application
    Filed: November 1, 2021
    Publication date: April 21, 2022
    Inventors: Taylor SCHREIBER, George FROMM, Suresh DE SILVA
  • CSF1R-based chimeric proteins
    Patent number: 11267857
    Abstract: The present invention relates, in part, to, chimeric proteins which include the extracellular domain of colony stimulating factor 1 receptor (CSF1R) and their use in the treatment of diseases, such as immunotherapies for cancer and/or an inflammatory disease.
    Type: Grant
    Filed: November 6, 2019
    Date of Patent: March 8, 2022
    Assignee: Shattuck Labs, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
  • CSF1R-CD40L chimeric proteins
    Patent number: 11267856
    Abstract: The present invention relates, in part, to, chimeric proteins which include the extracellular domain of colony stimulating factor 1 receptor (CSF1R) and their use in the treatment of diseases, such as immunotherapies for cancer and/or an inflammatory disease.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: March 8, 2022
    Assignee: Shattuck Labs, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
  • HETERODIMERIC PROTEINS FOR MODULATING GAMMA DELTA T CELLS
    Publication number: 20220025000
    Abstract: The present technology relates, inter alia, to compositions and methods, including heterodimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity.
    Type: Application
    Filed: July 16, 2021
    Publication date: January 27, 2022
    Inventors: Taylor SCHREIBER, George FROMM, Suresh DE SILVA
  • COMBINATION THERAPIES COMPRISING SIRP ALPHA-BASED CHIMERIC PROTEINS
    Publication number: 20210379153
    Abstract: The present invention relates to, inter alia, combinations of compositions which include chimeric proteins that find use in methods for treating disease, such as immunotherapies for cancer and autoimmunity.
    Type: Application
    Filed: August 29, 2019
    Publication date: December 9, 2021
    Inventors: Taylor SCHREIBER, George FROMM, Suresh DE SILVA